Prospective study investigating efficacy of lanreotide on decrease of chemotherapy induced diarrhoea (CID) in patiens with colorectal carcinoma.
Phase of Trial: Phase III
Latest Information Update: 27 Jul 2018
At a glance
- Drugs Lanreotide (Primary)
- Indications Chemotherapy-induced damage; Diarrhoea
- Focus Therapeutic Use
- Acronyms STOPRHEA
- 24 Jul 2018 Status changed from recruiting to discontinued.
- 10 Mar 2017 New trial record